Selpercatinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 493 publications
Adjuvant selpercatinib shows benefit in patients with NSCLC.
Journal: Nature reviews. Clinical oncology
Published: June 11, 2026
Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.
Journal: JCO precision oncology
Published: June 08, 2026
RET Fusion-Positive Solid Tumor
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 04, 2026
Selpercatinib Improves EFS in RET Fusion-Positive NSCLC.
Journal: Cancer discovery
Published: June 02, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
RET-positive neuroendocrine lung cancer in pregnancy with placental metastases.
Journal: BMJ case reports
Published: May 22, 2026
Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: May 20, 2026
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
Journal: Thyroid : official journal of the American Thyroid Association
Published: May 12, 2026
FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.
Journal: Pharmacological research
Published: May 05, 2026
Efficacy of selpercatinib as a first-line treatment for RET-fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis.
Journal: Journal of comparative effectiveness research
Published: April 29, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 17, 2026
Last Updated: 06/30/2026